Clemency Nye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Clemency Nye has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Underwood
Division of Infection and Immunity, Cardiff University, Cardiff, UK
2 shared publications - Aimee McGreal-Bellone
Department of Infectious Diseases, Beaumont Hospital , Dublin , Ireland
1 shared publication Alice Maxwell
Public Health Wales, University Hospital of Wales, Heath Park, Cardiff, CF14 XW
1 shared publicationAlina Botgros
Directorate of Infection, Guy’s & St Thomas’ National Health Service Foundation Trust , London , UK
1 shared publication- Brendan O'KElly
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland
1 shared publication - Catherine Moore
Public Health Wales, Heath Park, Cardiff, UK
1 shared publication
Latest Publications
- Open Access
- 9 December 2023
- Published by Elsevier in Clinical Infection in Practice
- Vol. 21, 100336
Enterococcus faecalis bacteraemia and infective endocarditis - what are we missing?
- 9 December 2023
- Published by Elsevier in Clinical Infection in Practice
- Vol. 21, 100336
Open AccessEnterococcus faecalis bacteraemia and infective endocarditis - what are we missing?
- Open Access
- 7 December 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (1) , ofad612
A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir
The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where persistent SARS-CoV-2 infection was successfully treated with prolonged courses (median, 10 days [range, 10–18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most cases (9/11) had hematological malignancy and 10 (10/11) had received CD20-depleting therapy. The median duration of infection was 103 days (interquartile range, 85–138 days). The majority (10/11) were hospitalized, and 7 (7/11) had severe/critical disease. All survived and 9 of 11 demonstrated viral clearance, almost half (4/9) of whom received nirmatrelvir/ritonavir as monotherapy. This case series suggests that prolonged nirmatrelvir/ritonavir has a role in treating persistent infection.
- 7 December 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (1) , ofad612
Open AccessA Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir
The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where persistent SARS-CoV-2 infection was successfully treated with prolonged courses (median, 10 days [range, 10–18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most cases (9/11) had hematological malignancy and 10 (10/11) had received CD20-depleting therapy. The median duration of infection was 103 days (interquartile range, 85–138 days). The majority (10/11) were hospitalized, and 7 (7/11) had severe/critical disease. All survived and 9 of 11 demonstrated viral clearance, almost half (4/9) of whom received nirmatrelvir/ritonavir as monotherapy. This case series suggests that prolonged nirmatrelvir/ritonavir has a role in treating persistent infection.
- Open Access
- 28 October 2022
- Published by Microbiology Society in Access Microbiology
- Vol. 4 (10) , 000413
Cefiderocol to manage chronic, multi-drug-resistant Burkholderia cepacia complex infection in a patient with cystic fibrosis: a case report
In cystic fibrosis (CF) patients, Gram-negative Burkholderia cepacia complex (Bcc) infections are associated with recurrent pulmonary exacerbations. Bcc organisms are innately resistant to many antibiotics, and infection with B. cenocepacia is a contraindication to lung transplantation. We report a CF patient with severe lung disease, colonized with Bcc, with a history of around nine exacerbations per year for over 10 years, for whom antibiotic regimens (including targeted and broad-spectrum antibiotics) had not cleared infection or extended the interval between exacerbations. After receiving a 2 week cefiderocol-containing regimen, the patient remained stable for more than 5 months without the need for additional antibiotics or hospital admissions for respiratory exacerbations.
- 28 October 2022
- Published by Microbiology Society in Access Microbiology
- Vol. 4 (10) , 000413
Open AccessCefiderocol to manage chronic, multi-drug-resistant Burkholderia cepacia complex infection in a patient with cystic fibrosis: a case report
In cystic fibrosis (CF) patients, Gram-negative Burkholderia cepacia complex (Bcc) infections are associated with recurrent pulmonary exacerbations. Bcc organisms are innately resistant to many antibiotics, and infection with B. cenocepacia is a contraindication to lung transplantation. We report a CF patient with severe lung disease, colonized with Bcc, with a history of around nine exacerbations per year for over 10 years, for whom antibiotic regimens (including targeted and broad-spectrum antibiotics) had not cleared infection or extended the interval between exacerbations. After receiving a 2 week cefiderocol-containing regimen, the patient remained stable for more than 5 months without the need for additional antibiotics or hospital admissions for respiratory exacerbations.